There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Veru (VERU – Research Report) and GH Research (GHRS – Research Report) with bullish sentiments.
Veru (VERU)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Veru today and set a price target of $3.00. The company’s shares closed last Friday at $1.65.
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Veru is a Strong Buy with an average price target of $3.67.
See the top stocks recommended by analysts >>
GH Research (GHRS)
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on GH Research, with a price target of $39.00. The company’s shares closed last Friday at $11.46.
According to TipRanks.com, Butler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
GH Research has an analyst consensus of Strong Buy, with a price target consensus of $39.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VERU:
- Veru to present at the GLP-1 Based Therapeutics Summit
- Veru to Present at the GLP-1 Based Therapeutics Summit
- Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
- Veru enrolls first patients in Phase 2b trial of enobosarm, semaglutide
- Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
